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ABSTRACT  
 
Background and Aims 
There is evidence vitamin D may be immunomodulatory and alter faecal microbiota, but 
results from clinical studies in humans to date have been inconclusive. This study aimed to 
assess the effect of vitamin D replacement in vitamin D deficient patients with and without 
ulcerative colitis (UC) on inflammation and faecal microbiota. 
 
Methods 
Vitamin D was replaced over 8 weeks in patients with active UC (defined by faecal 
calprotectin ≥100 µg/g), inactive UC (faecal calprotectin <100 µg/g), and non-IBD controls 
with baseline 25(OH) vitamin D <50 nmol/L, and markers of inflammation and faecal 
microbiota analysed.  
 
Results 
Eight patients with active UC, 9 with inactive UC and 8 non-IBD controls received 40,000 
units cholecalciferol weekly for 8 weeks. Mean baseline 25(OH) vitamin D increased from 34 
(range 12-49) nmol/L to 111 (71-158) nmol/L (p <0.001), with no difference across the 
groups (p = 0.32). In patients with active UC, faecal calprotectin levels reduced from median 
275 to 111µg/g (p = 0.02), platelet count reduced (mean 375 to 313x10
9
/L, p = 0.03), and 
albumin increased (mean 43 to 45g/L, p = 0.04). These parameters did not change in patients 
with inactive UC or non-IBD controls. No changes in overall faecal bacterial diversity were 
noted although a significant increase in Enterobacteriaceae abundance was observed in 
patients with UC (p = 0.03).  
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Conclusions 
Vitamin D supplementation was associated with reduced intestinal inflammation in patients 
with active UC, with a concomitant increase in Enterobacteriaceae but no change in overall 
faecal microbial diversity.  
 
Key words: Basic science, experimental models and pathophysiology; clinical trials 
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INTRODUCTION 
With expanding therapeutic options for inflammatory bowel diseases (IBD), costs associated 
with medical therapies have risen disproportionately to those associated with disease 
complications 
1
. Numerous epidemiological and laboratory-based immunological studies 
support the role of vitamin D as a potential inexpensive immunomodulator, and serum 
25(OH) vitamin D (25(OH)D) status has been shown to be inversely proportional to intestinal 
inflammation in patients with IBD 
2-8
. However, there remains a paucity of interventional 
data supporting it as a treatment for patients with IBD. 
 
Dysbiosis, or dysregulation of the gut microbiota, is a recognised feature of IBD, and is 
thought to play a role in the pathogenesis and perpetuation of inflammation 
9
. Patients with 
UC have reduced bacterial species richness, as well as temporal instability of the microbiota 
profile in clinical remission and in active disease, compared with healthy controls 
10-12
. 
Members of the Firmicutes and Bacteroidetes phyla have been demonstrated to be reduced 
10
. 
Increases in pathobiont bacterial species including Fusobacterium nucleatum and Escherichia 
coli have been shown in the mucosa and faeces of patients with UC 
13, 14
, whilst the 
immunoregulatory species Faecalibacterium prausnitzii, has been shown to be under-
represented 
15
. Mucolytic bacterial species including Ruminococcus gnavus and 
Ruminococcus torques are also disproportionately increased in abundance in patients with 
IBD with the suggestion being that increased numbers contributes towards the gut 
environment changes seen as the disease progresses 
16
. Therapeutically targeting the 
microbiota using the broad approach of faecal microbiota transfusion has been shown to 
improve outcomes in patients with UC 
17-19
. 
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There is evidence to suggest that vitamin D may modify the gut microbiota. Specifically, 
vitamin D supplementation has been shown to suppress intra-macrophage Escherichia coli 
survival in in vitro studies 
20
. Vitamin D has also been shown to regulate anti-microbial 
peptide production 
20-22
. Vitamin D deficient and vitamin D receptor (VDR) knockout mice 
have reduced ileal Paneth cell alpha defensin secretion, increased abundance of Helicobacter 
hepaticus, and reduced abundance of Akkermansia muciniphila, compared with control or 
wild-type mice 
23
. Studies have also shown that VDR negatively regulates bacterial-induced 
intestinal epithelial NFκB activation and response to infection 24. Conversely, a cross-
sectional study of 150 young healthy adults found an inverse correlation between 25(OH)D 
status and faecal abundance of the butyrate-producing bacterium Coprococcus and 
Bifidobacterium, both of which may theoretically mediate an anti-inflammatory effect 
25
. It is 
currently unknown whether vitamin D supplementation in patients with UC affects pro-
inflammatory or anti-inflammatory gut microbiota as part of a strategy to influence disease 
activity.  
 
This prospective pilot study aimed to evaluate change in subjective and objective markers of 
intestinal inflammation, and within the faecal microbiota, following vitamin D replacement in 
patients with active and inactive UC, and non-IBD controls. 
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MATERIALS AND METHODS 
Subjects and study protocol 
Consecutive patients with vitamin D deficiency (defined by 25(OH)D < 50 nmol/L) attending 
outpatient clinics at St Mark’s Hospital were invited to participate. Three groups were 
studied: (1) those without IBD or other known gastrointestinal malabsorptive condition, (2) 
those with inactive UC (defined as faecal calprotectin < 100 µg/g), and (3) those with active 
UC (faecal calprotectin ≥ 100 µg/g) 26, 27. Inclusion criteria for patients with UC comprised 
partial Mayo score of ≤ 4, and stable therapy including mesalazine (≥2 months) and 
immunomodulatory or anti-tumour necrosis factor therapy (≥3 months) with no change in 
therapy planned for at least 12 weeks as per the patient’s treating clinician. Exclusion criteria 
included other significant gastrointestinal disease, pregnancy (current or planned within 6 
months), hypercalcaemia or evidence of primary or tertiary hyperparathyroidism, chronic 
kidney or severe cardiovascular disease, antibiotics within the previous 2 months or bowel 
preparation within the previous 4 weeks. 
 
Demographic and disease characteristics and activity as assessed by Simple Clinical Colitis 
Activity Index (SCCAI)
28, 29
 and Partial Mayo Index
30
 were recorded, patients were asked to 
complete a food diary, and blood tests collected for markers of inflammation. Serum 25(OH) 
levels were quantified using liquid chromatography tandem mass spectrometry. Patients were 
asked to provide two faecal specimens with the assistance of Stoolcatcher
TM
 (TagHemi, 
Zeijen, The Netherlands) as per manufacturer’s instructions, and supplied with an ice pack 
for transport to the hospital within 2 hours. One container was analysed for calprotectin (by 
enzyme linked immunosorbent assay, ELISA, Schottdorf Laboratories, Germany), and the 
second stored at -80 degrees Celsius for microbiota analysis.  
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Patients were prescribed vitamin D replacement according to the London North West 
Healthcare NHS Trust guidelines, at a dose of 40,000 IU once weekly for 8 weeks using 2 
capsules of 20,000 IU vitamin D3 (Plenachol, Encap, West Lothian, UK). Following 
replacement, patients were re-assessed symptomatically and by objective markers of 
inflammation, with repeat faecal microbiota analysis. Adherence was checked by direct 
patient questioning of number of capsules remaining. 
 
Faecal microbiota analysis 
DNA Extraction 
All samples were extracted within one month of collection using the Stratech PSP Spin Stool 
DNA kit following the manufacturer’s instructions.  
 
PCR amplification and sequencing. The V3-4 region of the 16S rRNA gene was amplified 
using Bakt_341F and Bakt_805R primers, as described previously 
31
, then pooled and 
purified using AMPure XP (Beckman Coulter, Brea, California, USA). The samples were 
then indexed using the Nextera XT Index Kit V2 (Illumina, San Diego, California, USA) 
and KAPA HiFi Hotstart ReadyMix (Kapa Biosystems, Cape Town, South Africa) with 
libraries were quantified using Quant-iT™ dsDNA Assay Kit HS (Thermo Fisher Scientific, 
Waltham, MA, USA). Sequencing was performed using an Illumina MiSeq sequencer 
(Illumina, San Diego, California, USA) using Illumina V3 chemistry and paired-end 2×300 
base pair reads. Further details regarding PCR amplification are presented in Supplementary 
Material 1. 
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Bioinformatic Analysis 
Quality of the sequences was assessed using FastQC (version 0.11.3) 
32
. The V3-V4 primer 
sequences at the 5’ end of reads were hard trimmed using TrimGalore! (version 0.4.0) 33. 
Sequences were analysed using DADA2 (version 1.3.1) to produce sequence variants.  
Taxonomy was assigned against the GreenGenes 13.8 database 
34
. The outcome sequence 
variant table was converted to biom format using biomformat (version 2.1.3) 
35
. Further 
details regarding bioinformatic analysis are presented in Supplementary Material 1. 
 
Diversity analyses including Simpson Index for alpha diversity and Bray-Curtis for beta 
diversity were performed using the core_diversity_analyses.py script from QIIME (version 
1.9.0) with a subsampling level of 19505 to ensure that all samples were included 
36
. Taxa 
numbers at each taxonomic level were also produced. LEfSe analysis was carried out using 
the Huttenhower Galaxy Server (http://huttenhower.sph.harvard.edu/galaxy/) to identify any 
potential biomarkers associated with sample types 
37
. DESeq2 analysis 
38
, Wilcoxon Rank 
sum tests and Kruskall-Wallis tests for significant changes in abundance in relation to sample 
type were carried out in R. A p-value of ≤ 0.05 was considered statistically significant, with 
the exception of DESeq2 analysis where an adjusted p value of ≤ 0.05 was used. Figures were 
made using ggplot2 in RStudio. PCoA plots were visualised using Emperor 
39
. 
 
Statistical considerations 
Statistical analyses for non-microbiota results were performed using SPSS v23 (IBM 
Corporation, Armonk, New York, 2015) and GraphPad Prism v5.04 (Graphpad software, La 
Jolla, California, 2010). Dependent and independent samples t-tests, Mann Whitney U test, 
analysis of variance (ANOVA) and Kruskall-Wallis tests were used where appropriate. 
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Associations with increases in 25(OH)D were examined by bivariate correlations. A p-value 
of ≤ 0.05 was considered statistically significant.  
 
Ethical statement 
The protocol for this study was approved by the Office of Research and Ethics at London 
Northwest Healthcare NHS Trust, and was performed in accordance with United Kingdom 
regulations and the principles of the Declaration of Helsinki 1954 and its later amendments. 
Informed consent was obtained from all individual participants included in this study. 
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RESULTS  
Twenty-five patients participated in this study from August to September 2015 (late Summer 
to Spring at 52
0
 North), with baseline characteristics outlined in Table 1. No significant 
demographic differences were noted across the three groups. A trend to higher BMI and waist 
circumference in non-IBD controls was seen. Most patients with UC had left-sided or 
extensive colitis of variable duration. 
 
Routine laboratory indices and circulating components of the vitamin D axis amongst 
participants at baseline are outlined in Table 2. As expected, faecal calprotectin was 
significantly higher amongst patients with active disease, and platelet counts higher, with a 
trend towards higher C-reactive protein. No significant differences across the groups in serum 
25(OH) D, calcium, phosphate or parathyroid hormone were noted. Baseline dietary patterns 
of the participants are outlined in Supplementary Table 1. Seven of the 25 participants had a 
vegetarian diet, with self-reported vegetable intake reported as >35 standard serves per week 
by the majority (14 of 25) participants. 
 
The follow-up visit took lace following 8 weeks of vitamin D replacement (mean duration 
58 days). Vitamin D replacement resulted in an increase in serum 25(OH)D across all 
participants from a mean of 34 (range 12-49) nmol/L to 111 (71-183) nmol/L (p < 0.001, 
paired t-test) (Figure 1). There was no significant difference in the increase in 25 (OH) 
vitamin D between the three groups (p = 0.316). All patients reported completion of the full 
course of supplementation (320,000 IU vitamin D) except two non-IBD controls (240,000 IU 
each), one patient each with inactive and active UC (280,000 IU each). One patient with 
active UC ceased mesalazine tablets (taken at 3.2g daily) during the course of therapy in the 
context of symptomatic improvement. All other patients continued usual therapy. No 
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significant change in dietary patterns over the study period were observed across most 
subjects. 
 
Symptomatic disease activity indices significantly declined amongst patients with inactive 
and active colitis following vitamin D supplementation, reaching significance for SCCAI (p = 
0.04 and p = 0.01, respectively) but not for the Partial Mayo Score (p = 0.10 and p = 0.09, 
respectively). In patients with active UC, objective markers of disease activity significantly 
improved following vitamin D supplementation: faecal calprotectin (median 257 [range 110-
>2000] to median 111 [5-2000] µg/g, p = 0.02); platelet count (mean 375 [255-509] to mean 
313 [243-461] x 10
9
/L, p = 0.03); and albumin (mean 43 [38-49] to mean 45 [41-50] g/L, p = 
0.04) (Figure 1). No effect on faecal calprotectin, CRP, white cell count, platelet count or 
albumin was observed amongst patients with inactive colitis or non-IBD controls. Baseline 
overall dietary pattern, cereal and bread, vegetable or fruit intake did not influence response 
to faecal calprotectin, or circulating markers of inflammation, of vitamin D replacement (data 
not shown). 
 
Among patients with active UC, there was no significant correlation between the change in 
serum 25(OH)D and change in faecal calprotectin (Spearman r = -0.21, p = 0.61). There was 
no significant alteration in serum calcium, phosphate, or alkaline phosphatase. Serum 
parathyroid hormone levels declined significantly across the whole cohort (mean 4.0 [range 
2.2-5.7] to 3.4 [1.8-6.5] pmol/L, p = 0.02). No patients were hospitalised or required surgery. 
 
 
 
 
Downloaded from https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjy052/4991883
by University of Aberdeen user
on 03 May 2018
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjy052 
 
Change in faecal microbiota 
All twenty-five patients submitted a faecal sample at baseline, with twenty-three patients also 
providing a follow-up sample. One patient with active colitis and one non-IBD control did 
not submit follow-up samples for microbiota analysis.  
 
Between 50228 and 189688 raw sequences were produced per sample following amplicon 
sequencing. Post filtering and DADA2 analysis, each sample had between 19505 and 98075 
sequence variant counts with an average of 45734 counts (Supplementary Table 2). 
 
Diversity analyses 
No differences in alpha diversity as assessed by the Simpson, Shannon, Chao or Observed 
species diversity indices were noted across the three patient groups at baseline. No 
differences in alpha diversity were noted in samples following vitamin D replacement across 
the patient groups. 
 
Principal co-ordinate analysis (PCoA) plots using the Bray-Curtis beta diversity metric 
demonstrated that patients without IBD clustered together distinct from UC patients (Figure 
2a; p = 0.003, PERMANOVA). When the same analysis approach was applied to both the pre 
and post Vitamin D supplemented data, no difference between patients with inactive and 
active UC was noted (p = 1.0, Figure 2b).  
 
Taxonomic profiling 
Changes in the relative abundance of sequence variants showed statistically significant 
differences between the three groups at baseline (Table 3). Abundance of the mucus-
associated bacterium Ruminococcus gnavus was marginally but not significantly higher in 
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patients with UC than non-IBD controls (p = 0.068, Kruskall-Wallis, Supplementary Figure 
1). 
 
Change in abundance of specific bacteria following vitamin D administration were analysed 
using LEfSe analysis. Across all participants, an increase in Clostridium colinae (p = 0.03; 
driven by 2 non-IBD controls and 2 patients with inactive UC) and Enterobacteriacae (p = 
0.03; driven by 5 patients with inactive UC and 3 with active UC) was noted. Ruminococcus 
gnavus marginally but not significantly reduced following vitamin D supplementation across 
the whole cohort (p = 0.15; Wilcoxon Rank sum, Supplementary Figure 1). No significant 
change in abundances of other mucus-associated bacteria Ruminococcus torques or 
Akkermansia muciniphila, butyrate-producing bacteria from the Clostridium Cluster IV or 
Cluster XIVa groups, or of lactic acid producing bacteria (Lactobacilli or Bifidobacteria), or 
of the invasive bacteria Fusobacterium nucleatum and E. coli were noted (data not shown). 
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DISCUSSION 
The role of vitamin D as a potential immunomodulator in patients with IBD has been 
investigated extensively for over a decade. Numerous studies demonstrate involvement of the 
vitamin D axis in regulation of the epithelial barrier, innate immune cell and T-cell function 
20, 21, 23, 24, 40-47
. Though there are some preliminary data suggesting that vitamin D may 
influence the intestinal microbiota in IBD, this has not been studied in humans. Furthermore, 
evidence for efficacy at the clinical level remains poor. This study is the first to show that 
vitamin D replacement in patients with active UC deficient in vitamin D improved objective 
markers of inflammation. Though this was associated with a significant increase in 
Enterobacteriacae in patients with UC, there was no change in overall diversity or other 
specific bacteria analysed.  
 
Previous studies have shown that vitamin D supplementation may be associated with reduced 
rates of relapse in patients with Crohn’s disease in remission when given at a dose of 1200 IU 
daily for 12 months 
2, and improved Crohn’s disease activity index (CDAI) and quality of life 
when given at up to 5000 IU daily for 24 weeks 
4
. An alternative placebo-controlled RCT 
showed no significant change in CDAI, quality of life, CRP or faecal calprotectin in patients 
given 2000 IU vitamin D daily for 3 months 
5
. In patients with UC, low vitamin D levels have 
been associated with greater disease activity, as assessed by symptoms, faecal calprotectin, 
and endoscopic activity, as well as increased risk of subsequent relapse 
7, 8, 48-50
. A small pilot 
study demonstrated reduction in symptomatic disease activity indices but not intestinal 
inflammation as measured by faecal calprotectin in patients with UC and Crohn’s colitis 51. 
No placebo-controlled studies in patients with UC have been reported to date. The current 
study is the first to show an improvement in objective markers of inflammation (faecal 
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calprotectin, albumin, platelet count) following vitamin D replacement, limited to the group 
of patients with active UC defined by faecal calprotectin ≥ 100 µg/g at baseline. 
 
The reason for the faecal calprotectin reduction in these patients warrants further 
consideration. Though it has been postulated that a 25(OH)D level higher than 75 nmol/L, or 
closer to 100-125 nmol/L, may be required for immunomodulatory effect 
4, 48, 51-53
, such a 
level was not specifically targeted in this study. Rather, high dose oral weekly 
supplementation according to local institutional guidelines was administered at the same dose 
in all patients, as opposed to daily supplementation in most previous studies. Significant 
inter-individual variation in response to vitamin D supplementation exists, particularly in 
diseased states like IBD 
54
, and unsurprisingly the serum 25(OH)D level achieved varied 
from 75 to 183 nmol/L across the patients with UC. Five of 8 patients with active UC 
achieved a 25(OH)D of ≥ 100 nmol/L, all of whom had a reduction in faecal calprotectin to 
varying extents; however, there was no clear correlation between the rise in 25(OH)D and 
reduction in faecal calprotectin. Therefore, the findings in this study raise the prospect that it 
may not be the final serum 25(OH)D level, but the administration of a higher dose of vitamin 
D itself that potentially confers an immunomodulatory effect. This concept requires further 
investigation in an appropriately powered prospective controlled trial. 
 
The VDR is expressed in colonic intestinal epithelial cells, dendritic cells and macrophages 
21, 42
. Vitamin D has been shown to potently stimulate cathelicidin, an anti-microbial peptide 
produced by macrophages 
22
 which plays an important role in defence against intracellular 
organisms such as mycobacteria 
21
. VDR expression is significantly increased in inflamed 
and non-inflamed mucosal biopsies from patients with UC 
55
. Vitamin D supplementation 
suppressed intra-macrophage E. coli survival in in vitro studies 
20
, and vitamin D deficient 
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and VDR knockout mice had impaired ileal Paneth cell alpha defensin secretion and 
increased abundance of the colitogenic Helicobacter hepaticus, compared with control or 
wild-type mice 
23
. Therefore, there is biological plausibility for an interaction between the 
vitamin D axis and intestinal microbiota in the pathogenesis and perpetuation of 
inflammation in patients with IBD, especially UC. In the current study, no overall change in 
faecal microbial diversity occurred following vitamin D supplementation. Although an 
increase in the abundance of Enterobacteriaecae was noted following vitamin D 
supplementation in patients with UC, this large family comprises a large proportion of 
harmless and commensal as well as potentially pathogenic bacteria in the human gut, and 
therefore the significance of such a change is uncertain.  
 
Ruminococcus gnavus is a Gram-positive anaerobic mucolytic bacterium belonging to Cluster 
XIVa of the Clostridia class, which is increased in abundance in patients with IBD 
16
. The 
intestinal mucus layer provides a protective barrier between the luminal environment and 
mucosa, comprising dense glycoproteins interspersed with antimicrobial peptides produced 
by Paneth cells and other epithelial cells 
56
. A previous study has shown reduced abundance 
of Ruminococcus gnavus in mucosal biopsies from patients with active UC defined 
symptomatically 
57
, and this trend was confirmed in the current study, albeit without 
statistical significance. Furthermore, abundance of Ruminococcus gnavus non-significantly 
reduced across all patients after vitamin D supplementation. Whether vitamin D 
supplementation mediates regulation of intestinal mucus antimicrobial composition and 
therefore susceptibility to specific mucolytic bacteria, warrants further investigation.  
 
Nonetheless, an absence of significant effect on the faecal microbiota across the whole cohort 
of patients studied is worth noting. It is possible that vitamin D does not alter human 
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microbiota, despite laboratory data from mouse studies 
23
. Other possible explanations 
include a differential effect on faecal and mucosa-associated microbiota. Faecal microbiota 
was assessed during this study rather than mucosal associated microbiota as this is less 
invasive and is not subject to variation as a result of bowel preparation 
58
. However, given the 
intimate relationship between vitamin D induced anti-microbial peptide secretion and the 
mucosal microbiota, one may postulate that significant changes in the latter may be more 
reflective of the effect of vitamin D in this setting. An absence of significant alteration of the 
faecal microbiota by vitamin D supplementation, however, is not an isolated finding: despite 
widespread use, there remains a paucity of published data regarding the effect of 
conventional therapies such as 5-aminosalicylates, thiopurines and anti-TNFα agents on the 
faecal microbiota independent of changes in mucosal inflammation in patients with IBD 
59, 60
. 
Conversely, the absence of a change in microbiota composition despite reduction in 
inflammation in the active UC group is also notable, and may be reflective of only a mild 
reduction in inflammation in these patients. It is important to note that there are few robust 
data regarding change in microbiota composition in patients with UC in the absence of 
medical therapy 
61
. Furthermore, patients with UC in this study had a relatively long disease 
duration, with a median of 11-12 years. Data regarding the effect of duration of UC on 
temporal variability of microbiota are also limited 
61
. Longer disease duration has previously 
been described as a risk factor for vitamin D deficiency 
62
, but no influence of disease activity 
on initial 25(OH)D level or response to supplementation was noted in the current study (data 
not shown). 
 
There are multiple other limitations in this small study. Though no overt toxicity as measured 
by serum calcium and phosphate was noted, long-term potential effects of the 
supplementation strategy in this study were not able to be elucidated, particularly the risk of 
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hypercalciuria or nephrocalcinosis 
51
. Dietary assessment of patients at baseline and follow-
up visits showed no clear changes across most patients, but specific effects of change in diet 
as confounders were difficult to elicit. 
 
In conclusion, vitamin D supplementation at a dose of 40,000 IU weekly for 8 weeks reduced 
objective circulating and intestinal markers of inflammation in patients with active UC. A 
significant increase in abundance of Enterobacteriaceae in patients with UC, and a trend to 
reduction in the mucolytic Ruminococcus gnavus species, was noted, but overall microbiota 
diversity was unchanged. Vitamin D may therefore reduce intestinal inflammation, but 
independently of change in faecal bacterial composition. A larger placebo-controlled clinical 
trial incorporating immunological and extended microbiota analyses, including functional 
assessment, will shed further light upon this effect. 
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FIGURE LEGENDS 
 
Figure 1. Change in clinical and laboratory indices following vitamin D 
supplementation in participants without IBD, those with inactive and active UC. 
 
Figure 2. Principal Co-ordinate Analysis (PCoA) Plots at (a) baseline and (b) before and 
following vitamin D supplementation 
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Table 1. Baseline participant characteristics. (DM, diabetes mellitus; BMI, body mass 
index; SCCAI, Simple Clinical Colitis Activity Index; Fitzpatrick skin types: I - pale white 
skin, blue/hazel eyes, blond/red hair, II - fair skin, blue eyes, III - darker white skin, IV - light 
brown skin, V - brown skin, VI - dark brown or black skin). 
 
 Non-IBD 
Controls 
(n = 8) 
Inactive UC 
(n = 9) 
Active 
UC 
(n = 8) 
P value  
Age (mean +/- range) 51 (35-66) 45 (28-72) 45 (30-68) 0.541
a 
Female:Male 3:5 3: 6 4:4 0.793
a 
Ethnicity, n (%)     
British White 3 1 1  
Southern European 0 0 2  
Indian Subcontinental 5 7 5  
Arab & Middle Eastern 0 1 0  
Fitzpatrick Skin Type, n (%)     
I 0 0 0  
II 1 1 3  
III 2 1 0  
IV 0 1 0  
V 5 6 5  
VI 0 0 0  
Co-morbid illnesses, n (%)     
Hypertension 3 1 3  
Hyperlipidaemia 2 1 1  
Type 2 DM 1 0 1  
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Asthma 0 3 1  
Congestive cardiac failure 1 0 0  
Smoking status, n (%)    
 
Never smoked 5 6 6  
Ex-smokers 2 3 1  
Current smokers 1 0 1  
BMI (mean +/- range) 28.9 (23.5-
36.9) 
25.8 (20.5-
29.7) 
24.6 (21.5-28.4) 0.077
a 
Waist circumference, cm 
(mean +/- range) 
104 (93-119) 92 (84-99) 91 (70-109) 0.052
a 
Vitamin D supplementation, n 
(%) 
1 4 3 0.205
b 
Montreal Classification     
Disease extent: E1:E2:E3 NA 0:3:6 1:2:4  
UC Disease Duration, y 
(range) 
NA 11 (0.8-36) 12 (1-40)  
SCCAI (median, range) NA 2 (0-6) 3 (0-5)  
Partial Mayo Score (median, 
range) 
NA 0 (0-3) 1 (0-4)  
Medical therapy for UC NA    
Nil  1 1  
Mesalazine only  6 3  
Thiopurine +/- mesalazine  1 1  
Anti-TNF +/- mesalazine  1 0  
Vedolizumab +/- 
mesalazine 
 0 1  
Anti-TNF +/- thiopurine  0 2  
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a
 ANOVA 
b
 Chi-square, UC vs non-IBD controls 
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Table 2. Routine laboratory indices and components of the vitamin D axis in the patient groups and healthy controls. 
 
 Non-IBD Controls 
(n = 8) 
Inactive UC 
(n = 9) 
Active UC 
(n = 8) 
P value  
Haemoglobin (g/L, mean, range) 140 (118-155) 145 (122-167) 124 (87-154) 0.07
a
 
White cell count (X 10
9
/L, mean, range) 7.4 (4.9-10.0) 6.5 (4.9-8.0) 7.2 (5.3-10.6) 0.53
a
 
Platelet count (x 10
9
/L, mean, range) 266 (200-321) 241 (160-313) 375 (255-509) 0.001
a
 
Serum albumin (g/L, mean, range) 45 (42-50) 46 (43-51) 43 (38-49) 0.09
a
 
Serum C-reactive protein (mg/L, median, range) 1.0 (< 1.0-5.0) 1.0 (< 1.0-8.0) 4.0 (1.0-28.0) 0.054
b
  
Faecal calprotectin (µg/g, median, range) 16.4 (12.2-50.9) 34.2 (< 5.3-87.1) 257 (110->2000)
 
0.002
b
 
25(OH)D (nmol/L, mean, range) 31 (12-49) 33 (17-49) 34 (16-43) 0.90
a 
Serum calcium (corrected, mmol/L, mean, range) 2.42 (2.29-2.57) 2.44 (2.30-2.55) 2.46 (2.36-2.58) 0.67
a
  
Serum phosphate (mmol/L, mean, range) 1.06 (0.83-1.42) 1.02 (0.73-1.65) 0.99 (0.55-1.33) 0.85
a 
Serum PTH (pmol/L, mean, range) 3.3 (2.2-4.7) 4.6 (3.7-5.7) 4.5 (2.7-5.6) 0.20
a 
a
 ANOVA 
b
 Kruskall-Wallis test 
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Table 3. Significant DESeq2 results comparing the relative abundance of sequence 
variants across sample types. All values given to three significant figures.  
 
Sequence Variant Taxonomy Log Fold Change Adjusted P Value 
Inactive UC > Non-IBD controls 
E. coli 5.34 0.00448 
Non-IBD Controls > Active UC 
Prevotella copri 8.48 0.0442 
Coprococcus genus 8.76 0.0294 
Inactive > Active UC 
Prevotella copri 8.46 0.00640 
Bacteroides plebeius 9.08 0.0131 
Bacteroides fragilis 8.79 0.0158 
Bacteroides genus 7.83 0.0116 
Ruminococcaceae family 8.73 0.00927 
Bacteroides caccae 8.30 0.00640 
Coprococcus genus 6.62 0.0284 
Active > Inactive UC 
Lachnospira genus 6.03 0.00927 
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Sutterella genus 8.75 0.0158 
Coprococcus genus 6.62 0.0284 
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Figure 1. Change in clinical and laboratory indices following vitamin D supplementation in 
participants without IBD, those with inactive and active UC. 
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Figure 2. Principal Co-ordinate Analysis (PCoA) Plots at (a) baseline and (b) before and 
following vitamin D supplementation 
(a) 
 
(b)  
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